BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32797212)

  • 1. The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
    Becker DJ; Rude T; Walter D; Wang C; Loeb S; Li H; Ciprut S; Kelly M; Zeliadt SB; Fagerlin A; Lepor H; Sherman S; Ravenell JE; Makarov DV
    J Natl Cancer Inst; 2021 May; 113(5):626-631. PubMed ID: 32797212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
    Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
    Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.
    Frendl DM; Epstein MM; Fouayzi H; Krajenta R; Rybicki BA; Sokoloff MH
    Cancer Causes Control; 2020 Sep; 31(9):861-867. PubMed ID: 32556947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
    Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
    JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
    JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
    Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
    Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
    Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
    J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate Specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
    Alkhatib K; Labban M; Briggs L; Nguyen DD; Herzog P; Cole AP; Haag A; Trinh QD
    J Urol; 2022 May; 207(5):993-1000. PubMed ID: 34967663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic.
    Qian Z; Chen X; Cole AP; Abdollah F; Choueiri TK; Kibel AS; Lipsitz SR; Iyer HS; Trinh QD
    Eur Urol Oncol; 2024 Feb; 7(1):151-154. PubMed ID: 37487814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
    Fleshner K; Carlsson SV; Roobol MJ
    Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing aggressive prostate cancer.
    Shah N; Ioffe V; Chang JC
    Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.
    Partin MR; Lillie SE; White KM; Wilt TJ; Chrouser KL; Taylor BC; Burgess DJ
    Health Expect; 2017 Aug; 20(4):779-787. PubMed ID: 27807905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.